Navigation Links
The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
Date:8/30/2007

LAUSANNE, Switzerland, August 30 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, today presented the 'Debiopharm Life Sciences Award' to Hungarian scientist Dr Zoltan Nusser for his outstanding research in both fundamental and clinical neuroscience. Funded by Debiopharm and organised by the Ecole Polytechnique Federale de Lausanne (EPFL), the ceremony took place during the EPFL Life Science Symposium 2007. Dr Nusser and his institute received CHF 100'000 and an etched crystal tribute commemorating this honour.

"We were impressed with the quality of research conducted by Dr Nusser," said Rolland-Yves Mauvernay, President of Debiopharm Group. "And more importantly, his work could be applied to drugs that would make a difference to the lives of patients."

"The Debiopharm Life Sciences Award 2007 underscores the spectacular progress we have made in understanding the fundamental mechanisms involved in sensorial perception," added Patrick Aebischer, President of EPFL.

Dr Nusser's work, at the Hungarian Academy of Sciences of Budapest, focuses on understanding the sub cellular organisation and function of synapses in the central nervous system (CNS) and their involvement in neuronal network activities underlying sensory perception. The application of his research could lead to the development of new treatments for patients suffering from CNS diseases. He has received various prizes and has published his research in leading publications including Nature, Neuron and Proceedings of the National Academy of Sciences (PNAS).

About the Debiopharm Life Sciences Award

The Award was set up to mentor and motivate young innovative European researchers in the field of life sciences. Criteria for applications include novelty and originality of the work, as well as its importance and significance in connection with targeted therapeutic fields.

<
'/>"/>
SOURCE The Debiopharm Group
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Automation of the Eppendorf Perfectprep BAC 96 DNA Kit on the Caliper Life Sciences Sciclone ALH 3000
2. Perscitus Biosciences secures $250K Commerce loan
3. Wisconsin biosciences rise to the challenge
4. Wisconsin professors elected to National Academy of Sciences
5. Quintessence Biosciences advances cancer drug
6. Quintessence Biosciences names new president
7. InvivoSciences receives NIH grant for heart technology
8. Caden Biosciences may signal critical mass
9. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
10. QBI Life Sciences snags $130,000 NIH grant
11. WARF signs licensing pact with BD Biosciences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...FirstCall/--ArdeaBiosciences,Inc.(Nasdaq: RDEA )an...chiefexecutiveofficer,willpresentatthePiperJaffray...tailsareasfollows:,PiperJaffray21stAnnualHealthCa...p.m.EasternTime,Location:TheNewYorkPalaceHotel,New...t/ireye/,target=,_blank,title=,http://www.corpora...
(Date:11/24/2009)...ewswire/--Twomoreprestigiousuniversitieshavejoined...dcareerssiteforlifescienceprofessionals. ,, Nor...bboard,joining28othermajorlifesciencetrainingInsti...m ,isonlyforpost-graduatesinthelifesciences.Whilet...et,BioCareerCenteristheonlyonethatserveslifescienc...
(Date:11/24/2009)...4/PRNewswire-FirstCall/--deCODE,genetics,Inc.(Nasd...stday"motionsbytheU.S.BankruptcyCourtfortheDistric...iledavoluntarypetitionfor,reliefunderChapter11ofth.... , TheordersissuedbytheBankruptcyCourtallowt...hapter11proceedings.Inparticular,the,companyreceiv...
(Date:11/24/2009)...ecently approved the Promega PowerPlex 16 HS Syste...rating DNA records for the National DNA Index Syst...WEB) -- The FBI recently approved the Promega Pow...participating in, or generating DNA records for, t...y contains more than seven million profiles and ha...
Breaking Biology Technology:Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2
...ta Green, a Project Which Will Leverage Rosetta Ge...ng IP Position to Develop a Wide ...s Recently Secured Up to $1.5M From Private Invest...renches as Certain Milestones are ...fied microRNAs Correlated With Algal Oil Content ...
...howed Patients Experienced Improvements in Quality...th Other Anti-TNFs or Methotrexate, SAN FRANCISCO... that patients receiving every four week subcutane...0 mg, an investigational therapy,experienced signi...elated,quality of life (HRQOL) and fatigue. The da...
... Oct. 27 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,...cturer and supplier of,modernized traditional Chin... announced that the Company will present at the Ro... on Tuesday, November 11th, 2008. The,Conference w...ce Hotel in,New York City., The Company,s present...
Other Biology Technology:Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 2Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 3Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 4Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis 2Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis 3Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis 4Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis 5Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis 6Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis 7Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis 8Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis 9Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST 2Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST 3
(Date:11/26/2009)...cillin-resistant Staphylococcus Aureus ) and othe...as low-temperature plasma prototype devices have b...ling bactericidal cocktails. , Two prototype dev...ection of healthy skin (e.g. hands and feet) in ho...a lethal threat; and another to shoot bacteria-kil...
(Date:11/25/2009)...r 11, firefighters, police officers and ambulance ...rld Trade Center complex. They battled to save peo...survivors, tackled fires and evacuated as many peo...timated 17,000 people. And making their jobs even ...ghtened workers and their relatives jammed mobile ...
(Date:11/25/2009)...ate University assistant professors recently recei...NSF) to continue research beneficial to understand...00. , Christopher Blackwood, assistant professor...rded grants to support two separate research proje...ter Decomposer Communities and Functions from the ...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Magic box for mission impossible 2Magic box for mission impossible 3Kent State University professors focus research on the environment with grants totaling $890,000 2Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 1Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 2Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 3Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 4Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 5Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 6Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 7Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 8Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 9Is it Exam Time for Students Already 3F 56191 1Is it Exam Time for Students Already 3F 56191 2Is it Exam Time for Students Already 3F 56191 3Is it Exam Time for Students Already 3F 56191 4Is it Exam Time for Students Already 3F 56191 5Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug Resistant Influenza at 2009 ICAAC Annual Meeting 13842 1Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug Resistant Influenza at 2009 ICAAC Annual Meeting 13842 2
... research shows that certain genes can influence a...es, cancer for example. New research at the Masoni...tes that genetic markers may also show a person,s ...rch study led by Brian Van Ness, Ph.D., has succes... with early clinical relapse of multiple myeloma, ...
...LE, Ariz. Oct. 21, 2008 TGen has spun off its th...medical information source for oncologists. , The...on a variety of data sources, including genetic-ba...-based Translational Genomics Research Institute. ...e oncologists with the knowledge they need to desi...
...zambiquein response to the urgent need to reduce t... Council for Science (ICSU) has launched a new, 10...o address the gaps in the knowledge and methods th...ence to averting disasters and reducing risk. The ...eral Assembly in Maputo, Mozambique. , Each year ...
Other Biology News:U of MN study shows link between gene variations and cancer survival 2TGen spin-off MedTrust Online enables cancer doctors to quickly obtain best-available information 2International Council for Science launches major research program on natural disasters 2
...GFX Purification Kit, 24 reactions. For the genera....Optimized reagents are packaged together for comp...ptimized protocols can be used for performing labe...leotides.Reliable purification using the CyScribe ...
Canine serum from Equitech-Bio
UV-NIR light source for USB2000, HR4000, HR2000+ from Ocean Optics
Mouse Anti-Human SIGIRR Monoclonal Antibody, Unconjugated, Clone 162201 from R&D Systems
Biology Products: